Home Ingredients MonaJuventa™ Nu (Scarlet Beebalm / Didymin)
LongevityStress & AnxietySleep Health

MonaJuventa™ Nu (Scarlet Beebalm / Didymin)

Monarda didyma
Evidence Level
Limited
1 Clinical Trial
3 Documented Benefits
2/5 Evidence Score

MonaJuventa™ Nu is Mibelle's oral scarlet beebalm (Monarda didyma) extract standardized to the flavonoid didymin, marketed for healthy aging, stress and sleep. Its branded evidence combines laboratory work with a randomized, double-blind, placebo-controlled trial in stressed workers that reported a slower gain in an epigenetic-age measure and lower cortisol versus placebo. Honest framing: this is one manufacturer-sponsored 12-week trial, and its endpoints are surrogate markers, an epigenetic-clock style estimate of biological age plus cortisol. A smaller gain in an estimated biological age is not a demonstrated longevity, healthspan or disease outcome, and the finding has not been independently replicated.

Studied Dose Branded trial: 100 mg/day for 12 weeks. Taken as a capsule.
Active Compound Scarlet beebalm (Monarda didyma) extract standardized to the flavonoid didymin. MonaJuventa™ Nu is manufactured by Mibelle Biochemistry.

Benefits

Smaller gain in an epigenetic-age estimate (single branded RCT)

In a randomized, double-blind, placebo-controlled trial in stressed workers (45–65 y), 100 mg/day reduced the gain in a biological-age (epigenetic) measure and lowered cortisol versus placebo, alongside secondary, self-reported improvements in quality of life and sleep. These are surrogate laboratory and questionnaire measures, not evidence of a longer life, better healthspan or any disease outcome, and the single manufacturer-sponsored trial has not been independently replicated.

Supported by Trial 1

Stress and sleep support

Cortisol was lower than placebo in the single 12-week trial, which is consistent with stress-axis modulation. The sleep and wellbeing changes in that same trial were secondary, self-reported questionnaire outcomes, so treat them as preliminary rather than established.

Supported by Trial 1

Didymin flavonoid healthy-aging signaling

Didymin engages cellular stress-response and longevity pathways in laboratory (preclinical) models. That is mechanism only, the rationale behind the geroprotective positioning rather than evidence of a healthy-aging effect in people.

Supported by Trial 1

Mechanism of action

1

Cortisol / stress-axis modulation

Lower cortisol output is the proposed mechanism: chronically elevated cortisol is associated with stress-related aging, disrupted sleep and metabolic strain, so easing it is the plausible route to the effects reported in the trial.

2

Epigenetic / longevity-pathway signalling (proposed, preclinical)

Didymin has been reported to influence AMPK/FOXO-type stress-response signalling in laboratory models. This pathway work is preclinical, none of it was measured in the single human trial cited here, and it remains a proposed rather than a demonstrated mechanism.

Clinical trials

1
Scarlet Beebalm Geroprotection RCT

In vitro plus randomized, double-blind, placebo-controlled human trial, 100 mg/day for 12 weeks (GeroScience, 2025).

81 stressed workers aged 45–65

Over 12 weeks an estimated biological age (an epigenetic-clock style surrogate marker) rose less than with placebo, about 0.3 vs 1.8 years, with roughly 25% lower cortisol; quality-of-life and sleep gains were secondary, self-reported outcomes. Single manufacturer-associated trial with a surrogate endpoint, not a longevity or health outcome.

Side effects and drug interactions

Common Potential side effects

Generally well tolerated in the available trial.
Mild gastrointestinal upset possible.
Long-term and large-sample safety data are limited given the single study. Human exposure data are limited to one 12-week trial in 81 adults aged 45–65, so effects beyond 12 weeks, in other age groups and with repeated use are unknown; it is not a treatment for stress, insomnia or any age-related condition, and persistent sleep problems, fatigue or mood changes should be assessed by a clinician.
Pregnancy/lactation: not studied; precautionary avoidance reasonable.

Important Drug interactions

No clinically documented drug interactions have been reported, but that reflects how little this ingredient has been studied rather than an established clean safety profile; use theoretical caution with sedatives given the reported sleep effect.
Discuss with a clinician if on cortisol-affecting or psychiatric medications.

Featured in these supplement guides

Sleep & Insomnia→

More Longevity Ingredients

Longevity
GG-Gold® (Annatto-Derived Geranylgeraniol — American River Nutrition)
GG-Gold is American River Nutrition's annatto-derived trans-geranylgeraniol (GG), the worl…
Longevity
Multivitamin / Multimineral
A multivitamin combines a broad range of vitamins and minerals in one daily dose, serving…
Longevity
Veri-te™ Resveratrol (Evolva)
Branded yeast-fermented pharmaceutical-grade trans-resveratrol from Evolva (Switzerland).…
Longevity
Apigenin
Apigenin is a flavone abundantly found in parsley, chamomile, celery, and artichoke. Most…

Explore Other Ingredients

Cognitive
Ashwagandha
Ashwagandha (Withania somnifera) is an adaptogenic herb from Ayurvedic tradition, widely u…
Cognitive
Suntheanine®
Suntheanine® is a patented, 100% pure L-isomer theanine produced via an enzymatic process…
Sleep Health
Valerian Root
Valerian root is a traditional calming herb used for occasional sleeplessness and relaxati…

Frequently asked questions about MonaJuventa™ Nu (Scarlet Beebalm / Didymin)

What is MonaJuventa Nu?

It is an oral scarlet beebalm (Monarda didyma) extract from Mibelle, standardized to the flavonoid didymin and marketed for healthy aging, stress and sleep. In one manufacturer-sponsored 12-week trial it reported a smaller gain in an estimated epigenetic age (a surrogate marker) and lower cortisol than placebo.

Can a supplement really slow aging?

MonaJuventa Nu's trial used an epigenetic biological-age measure, not lifespan, and was a single manufacturer-associated study. No health, function or disease outcome was measured, and a slower epigenetic-clock reading has not been shown to translate into living longer or healthier. The cortisol finding is plausible and the sleep and wellbeing changes were secondary self-reported outcomes; the anti-aging claim is intriguing but unproven and needs independent replication.

What is MonaJuventa Nu used for?

MonaJuventa Nu is researched primarily for Longevity, Stress & Anxiety, and Sleep Health. In a randomized, double-blind, placebo-controlled trial in stressed workers (45–65 y), 100 mg/day reduced the gain in a biological-age (epigenetic) measure and lowered cortisol versus placebo, alongside secondary, self-reported improvements…

What is the recommended dosage of MonaJuventa Nu?

The clinically studied dose is Branded trial: 100 mg/day for 12 weeks. Taken as a capsule. Always follow the product label and check with a healthcare provider for personal advice.

Is MonaJuventa Nu safe, and does it have side effects?

For most healthy adults, MonaJuventa Nu is well tolerated at studied doses. Reported effects can include: Generally well tolerated in the available trial. Mild gastrointestinal upset possible. It may also interact with some medications. MonaJuventa Nu is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does MonaJuventa Nu interact with any medications?

Possible interactions include: No clinically documented drug interactions have been reported, but that reflects how little this ingredient has been studied rather than an established clean safety profile; use theoretical caution with sedatives given the reported sleep effect. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for MonaJuventa Nu?

NutraSmarts rates the evidence for MonaJuventa Nu as Limited (2 out of 5). It is backed by 1 clinical trial and 1 cited reference summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(1 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Campisi M, Cannella L, Paccagnella O, Brazzale AR, Agnolin A, Grothe T, et al. Unveiling the geroprotective potential of Monarda didyma L.: insights from in vitro studies and a randomized clinical trial on slowing biological aging and improving quality of life. GeroScience. 2025;47(3):4253-4290. doi: 10.1007/s11357-025-01580-2.PubMedUsed to support: The branded MonaJuventa Nu evidence: in vitro plus a randomized, double-blind, placebo-controlled human trial in stressed workers; scarlet beebalm (didymin) slowed an epigenetic-age measure and lowered cortisol versus placebo. Manufacturer-associated; a novel biological-age endpoint that warrants replication.